DK2147096T3 - Modificerede faktor-VII-polypeptider og anvendelser deraf - Google Patents
Modificerede faktor-VII-polypeptider og anvendelser deraf Download PDFInfo
- Publication number
- DK2147096T3 DK2147096T3 DK08742852.0T DK08742852T DK2147096T3 DK 2147096 T3 DK2147096 T3 DK 2147096T3 DK 08742852 T DK08742852 T DK 08742852T DK 2147096 T3 DK2147096 T3 DK 2147096T3
- Authority
- DK
- Denmark
- Prior art keywords
- factor vii
- modified factor
- vii polypeptides
- polypeptides
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92351207P | 2007-04-13 | 2007-04-13 | |
PCT/US2008/004795 WO2008127702A2 (en) | 2007-04-13 | 2008-04-11 | Modified factor vii polypetides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2147096T3 true DK2147096T3 (da) | 2015-06-15 |
Family
ID=39689319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08742852.0T DK2147096T3 (da) | 2007-04-13 | 2008-04-11 | Modificerede faktor-VII-polypeptider og anvendelser deraf |
Country Status (30)
Country | Link |
---|---|
US (1) | US20100166729A9 (da) |
EP (2) | EP2147096B1 (da) |
JP (3) | JP5761782B2 (da) |
KR (2) | KR20150067772A (da) |
CN (2) | CN101743309B (da) |
AU (1) | AU2008239586B2 (da) |
BR (1) | BRPI0810172A2 (da) |
CA (1) | CA2683443A1 (da) |
CO (1) | CO6231052A2 (da) |
CR (1) | CR11058A (da) |
DK (1) | DK2147096T3 (da) |
EC (1) | ECSP099735A (da) |
ES (1) | ES2537328T3 (da) |
GT (1) | GT200900268A (da) |
HK (1) | HK1134520A1 (da) |
HN (1) | HN2009002098A (da) |
IL (2) | IL201173A0 (da) |
MX (1) | MX2009010997A (da) |
NI (1) | NI200900187A (da) |
NZ (2) | NZ593611A (da) |
PH (1) | PH12014501960A1 (da) |
PL (1) | PL2147096T3 (da) |
PT (1) | PT2147096E (da) |
RU (1) | RU2571931C2 (da) |
SG (1) | SG174077A1 (da) |
SI (1) | SI2147096T1 (da) |
SV (1) | SV2009003393A (da) |
UA (1) | UA101155C2 (da) |
WO (1) | WO2008127702A2 (da) |
ZA (2) | ZA200906854B (da) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
US7939304B2 (en) * | 2002-10-02 | 2011-05-10 | Catalyst Biosciences, Inc. | Mutant MT-SP1 proteases with altered substrate specificity or activity |
SG166001A1 (en) * | 2002-10-02 | 2010-11-29 | Catalyst Biosciences Inc | Methods of generating and screening for proteases with altered specificity |
JP5629423B2 (ja) * | 2004-04-12 | 2014-11-19 | カタリスト バイオサイエンシーズ, インコーポレイテッド | 野生型及び変異型mt−sp1による、vegf及びvegf受容体の切断 |
AU2006304804B2 (en) * | 2005-10-21 | 2011-06-02 | Vertex Pharmaceuticals Incorporated | Modified proteases that inhibit complement activation |
EP2084274A2 (en) * | 2006-06-19 | 2009-08-05 | Nautilus Technology LLC | Modified coagulation factor ix polypeptides and use thereof for treatment |
ATE530644T1 (de) | 2006-07-05 | 2011-11-15 | Catalyst Biosciences Inc | Protease-screening-verfahren und dadurch identifizierte proteasen |
JP5761782B2 (ja) * | 2007-04-13 | 2015-08-12 | カタリスト・バイオサイエンシーズ・インコーポレイテッドCatalyst Biosciences, Inc. | 改変第vii因子ポリペプチド及びその使用 |
TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
EP2177624A1 (en) * | 2008-10-02 | 2010-04-21 | Siemens Healthcare Diagnostics Products GmbH | Blood coagulation assays |
AU2010266065B2 (en) | 2009-06-25 | 2016-01-14 | The University Of North Carolina At Chapel Hill | Chimeric Factor VII molecules |
GB0916578D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
DK2624859T3 (da) | 2010-10-06 | 2017-06-06 | Medimmune Ltd | Faktor ii alene eller i kombination med andre faktorer til behandlng af nedsat hæmostase i forbindelse med fortyndingskoagulopati |
US9677042B2 (en) | 2010-10-08 | 2017-06-13 | Terumo Bct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
PT3693025T (pt) | 2011-04-22 | 2022-01-20 | Univ California | Viriões de vírus adeno-associado com cápside variante e métodos de utilização dos mesmos |
WO2012149463A1 (en) * | 2011-04-29 | 2012-11-01 | The University Of North Carolina At Chapel Hill | Chimeric factor vii molecules with enhanced half life and methods of use |
EP2554161A1 (en) | 2011-08-02 | 2013-02-06 | LFB Biotechnologies | Pharmaceutical composition comprising factor VII encapsulated in micelles |
NZ626945A (en) * | 2012-01-12 | 2016-10-28 | Biogen Ma Inc | Chimeric factor viii polypeptides and uses thereof |
EP2838566A2 (en) | 2012-04-16 | 2015-02-25 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
WO2013177584A2 (en) * | 2012-05-25 | 2013-11-28 | The Children's Hospital Of Philadelphia | FVIIa VARIANTS EXHIBITING ALTERED INTERACTION WITH ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) AND METHODS OF USE THEREOF FOR MODULATING HEMOSTASIS |
US8986991B2 (en) * | 2012-07-03 | 2015-03-24 | Expression Therapeutics, Llc | High yield suspension cell line, system and method for making same |
BR112015001628A2 (pt) | 2012-07-25 | 2017-11-07 | Catalyst Biosciences Inc | polipeptídeos de fator x modificados e uso dos mesmos |
WO2014060397A1 (en) | 2012-10-15 | 2014-04-24 | Novo Nordisk Health Care Ag | Factor vii conjugates |
ES2945160T3 (es) | 2013-03-15 | 2023-06-28 | Gladiator Biosciences Inc | Dominios Gla como agentes terapéuticos |
JP6600624B2 (ja) | 2013-05-31 | 2019-10-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アデノ随伴ウイルス変異体及びその使用方法 |
CN103397009B (zh) * | 2013-08-16 | 2015-06-03 | 安源生物科技(上海)有限公司 | 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途 |
US9371370B2 (en) | 2013-10-15 | 2016-06-21 | Novo Nordisk Healthcare Ag | Coagulation factor VII polypeptides |
JP6612227B2 (ja) | 2013-11-16 | 2019-11-27 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
US10000741B2 (en) | 2014-03-17 | 2018-06-19 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
JP6783143B2 (ja) | 2014-03-25 | 2020-11-11 | テルモ ビーシーティー、インコーポレーテッド | 培地の受動的補充 |
PL3149163T3 (pl) * | 2014-05-26 | 2020-12-28 | Academisch Ziekenhuis Leiden | Białka prohemostatyczne do leczenia krwawienia |
WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
BR112017018846A2 (pt) | 2015-03-02 | 2018-07-31 | Adverum Biotechnologies, Inc. | composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos. |
JP6836999B2 (ja) | 2015-03-24 | 2021-03-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | アデノ随伴ウイルス変異体及びその使用方法 |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
CA3029833A1 (en) | 2016-07-29 | 2018-02-01 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
EP3528785A4 (en) | 2016-10-19 | 2020-12-02 | Adverum Biotechnologies, Inc. | MODIFIED AAV CASPIDS AND USES THEREOF |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
CN110612344B (zh) | 2017-03-31 | 2023-09-12 | 泰尔茂比司特公司 | 细胞扩增 |
CN111108196A (zh) * | 2017-05-09 | 2020-05-05 | 爱莫里大学 | 凝血因子变体及其用途 |
WO2018222503A1 (en) * | 2017-05-31 | 2018-12-06 | The Regents Of The University Of California | Adeno-associated virus with variant capsid and methods of use thereof |
US11680249B2 (en) | 2017-08-28 | 2023-06-20 | The Regents Of The University Of California | Adeno-associated virus capsid variants and methods of use thereof |
MX2020002250A (es) | 2017-09-05 | 2020-09-18 | Gladiator Biosciences Inc | Suministro de cargas utiles a las celulas madre. |
US12030925B2 (en) | 2018-05-18 | 2024-07-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
US11560556B2 (en) | 2018-08-03 | 2023-01-24 | Duke University | Protein C-factor VII chimeras |
EP3833381B1 (en) * | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
JP2024511064A (ja) | 2021-03-23 | 2024-03-12 | テルモ ビーシーティー、インコーポレーテッド | 細胞捕獲及び増殖 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5033352A (en) | 1989-01-19 | 1991-07-23 | Yamaha Corporation | Electronic musical instrument with frequency modulation |
US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
EP0521873B1 (en) * | 1990-01-29 | 1999-06-02 | Zymogenetics, Inc. | Anticoagulant proteins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1998035689A1 (en) | 1997-02-14 | 1998-08-20 | American Red Cross | Expression of active human factor ix in mammary tissue of transgenic animals |
US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
US20040087498A1 (en) * | 1991-02-28 | 2004-05-06 | Novo Nordisk Health Care Ag | Modified factor VII |
US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
DK1820858T3 (da) | 1991-03-01 | 2009-11-02 | Dyax Corp | Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf |
WO1992018619A1 (en) | 1991-04-10 | 1992-10-29 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US20050032690A1 (en) * | 1997-09-10 | 2005-02-10 | Rojkjaer Lisa Payne | Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia |
US6693075B1 (en) | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6017882A (en) | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6537749B2 (en) | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
DE19937219A1 (de) | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie |
AU1436401A (en) | 1999-10-21 | 2001-05-14 | Board Of Trustees Of The University Of Arkansas, The | RepO-associated virus AAV REP78 major regulatory protein, mutants thereof and uses thereof |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
EP2319541A1 (en) * | 2000-02-11 | 2011-05-11 | Bayer HealthCare LLC | Factor VII or VIIA-like conjugates |
US6905683B2 (en) * | 2000-05-03 | 2005-06-14 | Novo Nordisk Healthcare A/G | Human coagulation factor VII variants |
DE60143292D1 (de) | 2000-05-03 | 2010-12-02 | Novo Nordisk Healthcare Ag | Varianten des menschlichen Koagulationsfaktors VII |
ES2254414T3 (es) * | 2000-05-10 | 2006-06-16 | Novo Nordisk Health Care Ag | Composicion farmaceutica comprendiendo un factor vlla y un inhibidor tfpi. |
AU2001287550B2 (en) | 2000-09-13 | 2007-03-22 | Novo Nordisk Health Care Ag | Human coagulation factor VII variants |
CZ2003611A3 (cs) * | 2000-09-13 | 2003-08-13 | Novo Nordisk A/S | Varianty lidského koagulačního faktoru VII |
ES2323761T3 (es) * | 2000-10-02 | 2009-07-24 | Novo Nordisk Health Care Ag | Metodo para la produccion de proteinas dependientes de la vitamina k. |
AU2002218029A1 (en) * | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
EP1360490B1 (en) | 2001-01-23 | 2011-12-21 | President and Fellows of Harvard College | Nucleic-acid programmable protein arrays |
US20040133930A1 (en) | 2002-03-11 | 2004-07-08 | Cooper Julian D. | Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses |
AU2002249096B2 (en) | 2001-03-22 | 2007-06-28 | Novo Nordisk Health Care Ag | Coagulation factor VII derivatives |
US7235638B2 (en) * | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
AU2002315525A1 (en) * | 2001-07-03 | 2003-01-21 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon |
US7419949B2 (en) * | 2001-07-16 | 2008-09-02 | Novo Noridsk Healthcare A/G | Single-dose administration of factor VIIa |
US6882883B2 (en) * | 2001-08-31 | 2005-04-19 | Medtronic, Inc. | Implantable medical device (IMD) system configurable to subject a patient to a stress test and to detect myocardial ischemia within the patient |
US7052868B2 (en) * | 2001-09-27 | 2006-05-30 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
AU2002333211B2 (en) | 2001-09-27 | 2008-05-08 | Novo Nordisk Health Care Ag | Human coagulation factor VII polypeptides |
CN1309825C (zh) * | 2001-10-02 | 2007-04-11 | 诺和诺德医疗保健公司 | 在真核细胞中生产重组蛋白的方法 |
US20030143219A1 (en) * | 2001-10-09 | 2003-07-31 | Madison Edwin L | Nucleic acid molecules encoding a transmembrane serine protease 25, the encoded polypeptides and methods based thereon |
JP3862996B2 (ja) | 2001-10-31 | 2006-12-27 | 帝人ファイバー株式会社 | ポリトリメチレンテレフタレートフィラメント糸およびその製造方法 |
US6960657B2 (en) * | 2001-11-02 | 2005-11-01 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
US7291587B2 (en) * | 2001-11-09 | 2007-11-06 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides |
WO2003044179A2 (en) * | 2001-11-20 | 2003-05-30 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
PL370656A1 (en) * | 2001-12-21 | 2005-05-30 | Novo Nordisk A/S | Liquid composition of modified factor vii polypeptides |
ES2355713T3 (es) * | 2002-04-30 | 2011-03-30 | Bayer Healthcare Llc | Variantes polipeptídicas del factor vii o viia. |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
US20040001801A1 (en) * | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
DE60336555D1 (de) * | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
AU2003247776A1 (en) * | 2002-07-02 | 2004-01-23 | Dendreon Corporation | Serine protease 16 |
DE60315847T2 (de) | 2002-09-25 | 2008-05-15 | Novo Nordisk Health Care Ag | Varianten des menschliche koagulationsfaktors vii |
US6911323B2 (en) * | 2002-09-25 | 2005-06-28 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
EP1549677B1 (en) * | 2002-09-30 | 2011-04-13 | Bayer HealthCare LLC | FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY |
SG166001A1 (en) | 2002-10-02 | 2010-11-29 | Catalyst Biosciences Inc | Methods of generating and screening for proteases with altered specificity |
CA2519873C (en) * | 2003-03-20 | 2012-12-18 | Maxygen Holdings Ltd. | Fvii or fviia variants |
FI20030413A (fi) | 2003-03-20 | 2004-09-21 | Suomen Intech Oy | Kaasulaakerointi |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
US20040235054A1 (en) | 2003-03-28 | 2004-11-25 | The Regents Of The University Of California | Novel encoding method for "one-bead one-compound" combinatorial libraries |
WO2004108763A2 (en) | 2003-06-05 | 2004-12-16 | Canadian Blood Services | Mutants of the factor vii epidermal growth factor domain |
US20060116324A1 (en) * | 2003-06-13 | 2006-06-01 | Novo Nordisk Healthcare A/G | Novel formulations |
NZ573412A (en) | 2003-06-19 | 2010-09-30 | Maxygen Holdings Ltd | Factor VII or VIIa Gla domain variants |
JP4824559B2 (ja) * | 2003-09-09 | 2011-11-30 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 凝固因子viiポリペプチド |
EP1673453A2 (en) * | 2003-10-07 | 2006-06-28 | Novo Nordisk Health Care AG | Hybrid molecules having factor vii/viia activity |
US20070072271A1 (en) * | 2004-01-07 | 2007-03-29 | Novo Nordisk Healthcare A/G | Method for the production of recombinant proteins |
WO2005075635A2 (en) | 2004-02-03 | 2005-08-18 | Novo Nordisk Health Care Ag | Coagulation factor vii/viia variants lacking a functional lipid membrane binding domain |
JP5629423B2 (ja) * | 2004-04-12 | 2014-11-19 | カタリスト バイオサイエンシーズ, インコーポレイテッド | 野生型及び変異型mt−sp1による、vegf及びvegf受容体の切断 |
JP2008503541A (ja) | 2004-06-21 | 2008-02-07 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | グリコシル化分裂型因子vii変異体 |
WO2006014253A2 (en) * | 2004-07-02 | 2006-02-09 | Genentech, Inc. | Factor viia variants |
WO2006114105A2 (en) * | 2005-04-26 | 2006-11-02 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
EP2316930A1 (en) * | 2005-09-14 | 2011-05-04 | Novo Nordisk Health Care AG | Human coagulation factor VII polypeptides |
US20090011992A1 (en) * | 2005-09-21 | 2009-01-08 | Novo Nordisk Healthcare A/G | Human Coagulation Factor VII Polypeptides |
AU2006304804B2 (en) * | 2005-10-21 | 2011-06-02 | Vertex Pharmaceuticals Incorporated | Modified proteases that inhibit complement activation |
EP2084274A2 (en) * | 2006-06-19 | 2009-08-05 | Nautilus Technology LLC | Modified coagulation factor ix polypeptides and use thereof for treatment |
ATE530644T1 (de) * | 2006-07-05 | 2011-11-15 | Catalyst Biosciences Inc | Protease-screening-verfahren und dadurch identifizierte proteasen |
JP5761782B2 (ja) * | 2007-04-13 | 2015-08-12 | カタリスト・バイオサイエンシーズ・インコーポレイテッドCatalyst Biosciences, Inc. | 改変第vii因子ポリペプチド及びその使用 |
TWI538916B (zh) * | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
AU2010266065B2 (en) * | 2009-06-25 | 2016-01-14 | The University Of North Carolina At Chapel Hill | Chimeric Factor VII molecules |
TWI595004B (zh) * | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
BR112015001628A2 (pt) * | 2012-07-25 | 2017-11-07 | Catalyst Biosciences Inc | polipeptídeos de fator x modificados e uso dos mesmos |
-
2008
- 2008-04-11 JP JP2010503081A patent/JP5761782B2/ja not_active Expired - Fee Related
- 2008-04-11 KR KR1020157014839A patent/KR20150067772A/ko not_active Application Discontinuation
- 2008-04-11 KR KR1020097023568A patent/KR20100016462A/ko active IP Right Grant
- 2008-04-11 NZ NZ593611A patent/NZ593611A/en unknown
- 2008-04-11 RU RU2009141510/10A patent/RU2571931C2/ru not_active IP Right Cessation
- 2008-04-11 PT PT87428520T patent/PT2147096E/pt unknown
- 2008-04-11 ES ES08742852.0T patent/ES2537328T3/es active Active
- 2008-04-11 SG SG2011058658A patent/SG174077A1/en unknown
- 2008-04-11 EP EP08742852.0A patent/EP2147096B1/en active Active
- 2008-04-11 US US12/082,662 patent/US20100166729A9/en not_active Abandoned
- 2008-04-11 PL PL08742852T patent/PL2147096T3/pl unknown
- 2008-04-11 UA UAA200911564A patent/UA101155C2/ru unknown
- 2008-04-11 MX MX2009010997A patent/MX2009010997A/es active IP Right Grant
- 2008-04-11 EP EP12156573A patent/EP2481797A1/en not_active Withdrawn
- 2008-04-11 NZ NZ579985A patent/NZ579985A/en unknown
- 2008-04-11 WO PCT/US2008/004795 patent/WO2008127702A2/en active Application Filing
- 2008-04-11 CN CN200880016982.6A patent/CN101743309B/zh not_active Expired - Fee Related
- 2008-04-11 AU AU2008239586A patent/AU2008239586B2/en not_active Ceased
- 2008-04-11 BR BRPI0810172-8A2A patent/BRPI0810172A2/pt active Search and Examination
- 2008-04-11 SI SI200831442T patent/SI2147096T1/sl unknown
- 2008-04-11 CN CN201310367450XA patent/CN103451172A/zh active Pending
- 2008-04-11 DK DK08742852.0T patent/DK2147096T3/da active
- 2008-04-11 CA CA002683443A patent/CA2683443A1/en not_active Abandoned
-
2009
- 2009-09-24 IL IL201173A patent/IL201173A0/en unknown
- 2009-10-01 ZA ZA2009/06854A patent/ZA200906854B/en unknown
- 2009-10-08 CO CO09111636A patent/CO6231052A2/es unknown
- 2009-10-09 CR CR11058A patent/CR11058A/es not_active Application Discontinuation
- 2009-10-09 HN HN2009002098A patent/HN2009002098A/es unknown
- 2009-10-12 NI NI200900187A patent/NI200900187A/es unknown
- 2009-10-13 SV SV2009003393A patent/SV2009003393A/es unknown
- 2009-10-13 GT GT200900268A patent/GT200900268A/es unknown
- 2009-11-13 EC EC2009009735A patent/ECSP099735A/es unknown
-
2010
- 2010-03-10 HK HK10102495.4A patent/HK1134520A1/xx not_active IP Right Cessation
-
2011
- 2011-12-13 ZA ZA2011/09181A patent/ZA201109181B/en unknown
-
2012
- 2012-03-22 IL IL218776A patent/IL218776A0/en unknown
-
2013
- 2013-10-23 JP JP2013220232A patent/JP2014042523A/ja not_active Withdrawn
-
2014
- 2014-09-01 PH PH12014501960A patent/PH12014501960A1/en unknown
-
2016
- 2016-03-17 JP JP2016054083A patent/JP2016155836A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2147096T3 (da) | Modificerede faktor-VII-polypeptider og anvendelser deraf | |
DK2687596T3 (da) | Faktor VII-polypeptider som er modificerede og anvendelser deraf | |
DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
DK2209806T3 (da) | Anti-hepcidin-antistoffer og anvendelser deraf | |
DK2059535T3 (da) | Prlr-specifikt antistof og anvendelser deraf | |
DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
DK2220320T3 (da) | Forseglet enhed og mellemstykke | |
DK2160401T3 (da) | Fusionsmolekyler og il-15-varianter | |
DK2068887T3 (da) | SP35-antistoffer og anvendelser heraf | |
DK2139490T3 (da) | Diazo-bicykliske smac-mimetiske stoffer og anvendelser deraf | |
DK2913344T3 (da) | Specifikke bindingsproteiner og anvendelser deraf | |
DK3202779T3 (da) | Hgh polypeptider med langtidsvirkning og anvendelser deraf | |
DE602007010795D1 (de) | Blattsauger und -häcksler | |
DK2142529T3 (da) | Trpv1-antagonister og anvendelser deraf | |
DK2185164T3 (da) | Sammensætning og terapeutisk antitumorvaccine | |
DK1994055T3 (da) | Anti-5t4-antistoffer og anvendelser deraf | |
DK3663399T3 (da) | Modificerede factor IX-polypeptider og anvendelser deraf | |
DK3338790T3 (da) | Oligopeptid-forbindelser og anvendelser deraf | |
DK1894567T3 (da) | Ledsagende farmaceutiske midler og anvendelse deraf | |
DK2079485T3 (da) | Phenylpropionamidforbindelser og anvendelsen deraf | |
DK2012773T3 (da) | Lægemidler og anvendelser deraf | |
DK2001556T3 (da) | Thioninium-forbindelser og anvendelse deraf | |
DK2328931T3 (da) | Selektive anti-hepcidin-25-antistoffer og anvendelser deraf | |
DK2160336T3 (da) | Forbindelsesmekanisme og fremgangsmåde | |
DK2176284T3 (da) | Lantibiotika og anvendelser deraf |